Institutional Pharmacy Kickbacks: Buying the Recommendation Behind the Prescription

Institutional pharmacy pharmaceutical kickbacks buy a pharmacy’s influence over which drugs patients receive. A manufacturer can pay for recommendations to nursing homes or for programs that switch patients to its product. The payment may arrive as a rebate, a grant or a fee for data. If you work in pharmacy contracting, clinical programs or finance, you may see the commercial condition behind a recommendation presented as independent clinical judgment.

The Omnicare cases show how that influence can work. The government alleged that Amgen paid for programs designed to switch Medicaid beneficiaries to Aranesp, while Johnson & Johnson paid to have consultant pharmacists promote Risperdal and other drugs in nursing homes. These pharmaceutical kickback arrangements put the pharmacy between the manufacturer’s sales objective and the prescription.

How Do Pharmaceutical Kickbacks Work?

Pharmaceutical kickbacks work by giving someone value to influence a prescription, purchase or recommendation. In a long-term care pharmacy serving nursing homes, the manufacturer can reach the prescribing decision through the pharmacy’s drug-switching programs and consultant pharmacists. The person receiving the manufacturer’s money and the person signing the prescription can be different people.

A pharmacy does more than fill an order. RAND’s 2021 report, Prescription Drug Supply Chains: An Overview of Stakeholders and Relationships, describes how pharmacies can contact physicians to initiate a switch from a nonpreferred brand to a preferred one. The same report explains how hospital formularies and pharmacy policies influence prescribers’ choices among therapeutic alternatives.

Therapeutic interchange is a program for switching drugs. In the Amgen allegations, the program was designed to move Medicaid patients from a competitor’s drug to Aranesp. That gives the payment a specific commercial objective: move prescriptions to the product whose manufacturer is paying.

The financial records can sit apart from the drug’s journey. Drugs generally move from manufacturers through wholesalers to dispensers. A rebate, grant or data-purchase payment can connect the manufacturer and pharmacy separately. A purchasing invoice explains what the pharmacy bought. The manufacturer’s agreement can explain what it expected the pharmacy to do.

The neighboring pharmacy benefit manager rebate and formulary arrangements concern another source of influence over drug choice: the benefit manager’s coverage decisions. Omnicare’s consultant-pharmacist channel allegedly reached the recommendations nursing homes received.

Amgen and Omnicare’s Aranesp Interchange Program

The government alleged that Omnicare solicited and received Amgen kickbacks in return for therapeutic-interchange programs designed to switch Medicaid beneficiaries to Aranesp. The alleged payments rewarded the pharmacy for moving business to a particular manufacturer’s drug.

The alleged package included performance-based rebates tied to market-share or volume thresholds. It also included grants, speaker fees, consulting services, data fees, dinners and travel. Those forms belong together because the government’s allegation concerned what the combined arrangement bought: a program designed to change prescriptions.

Market-share and volume targets put the pharmacy’s financial interest beside the drug-selection decision. The threshold, the payment calculation and the interchange program are connected parts of the alleged bargain.

Omnicare agreed to a $4.19 million civil settlement announced in February 2014. A whistleblower brought the case under the False Claims Act.

A separate Amgen complaint shows the same market-share incentive in a hospital setting. The whistleblower alleged:

The hospital allegation makes the incentive unusually clear. The rebate allegedly depended on the manufacturer’s gain inside that particular institution. A contracting employee who understands how the rebate was calculated can explain what the sales target meant in practice. In Omnicare’s case, the government connected that kind of incentive to a pharmacy program for switching Medicaid patients.

Janssen and Omnicare’s Nursing-Home Recommendations

The Johnson & Johnson and Janssen allegations concerned payments intended to turn Omnicare’s consultant pharmacists into a channel for promoting Risperdal and other Johnson & Johnson drugs. The alleged package used market-share rebates, data-purchase agreements, grants and educational funding.

The Justice Department’s settlement announcement put the manufacturer’s expected return in operational terms:

The government alleged that J&J treated the pharmacists as an extension of its sales force while they purported to provide independent clinical recommendations. Nursing-home residents were supposed to benefit from independent clinical advice. Under the alleged arrangement, the manufacturer was buying influence over that advice to sell more drugs.

For a consultant pharmacist, that makes the origin of an intervention program consequential. Which drug did it favor? What did the pharmacy ask its pharmacists to recommend? How did those recommendations fit the manufacturer’s agreement? Those are the connections we examine with an insider who knows how the program operated.

Johnson & Johnson’s civil settlement for the Omnicare allegations was $149 million, announced in November 2013, compared with Omnicare’s earlier $98 million civil settlement in 2009 covering its alleged acceptance of Johnson & Johnson and Janssen kickbacks and other conduct. Both the company seeking more prescriptions and the pharmacy whose recommendations could deliver them paid to resolve allegations about the relationship.

The department also identified $27.7 million for the Massachusetts whistleblowers from the federal share of the manufacturer’s settlement.

Another Pharmacy Channel, the Same Paid Recommendation

Novartis allegedly used specialty-pharmacy rebates to buy recommendations that doctors switch patients to Myfortic. This parallel reaches a different pharmacy setting but makes the recommendation itself just as visible.

In its November 2015 settlement announcement, the Justice Department described a rebate offer made after a pharmacy owner agreed to create a letter recommending that doctors move patients to Myfortic. The alleged bargain connected the rebate contract to a communication aimed directly at prescribers.

The same announcement described a separate Exjade program in which Novartis allegedly allocated more patient referrals and higher rebates to pharmacies achieving higher refill rates. The government said Novartis used its control over referrals to press pharmacies to encourage refills through calls presented as education or clinical counseling.

A letter, a counseling call and a consultant-pharmacist recommendation can each carry the manufacturer’s sales objective through someone the prescriber or patient encounters as a healthcare provider. That is the pattern these pharmacy cases share.

What Are Red Flags for Pharmacists?

Institutional pharmacy interchange payments, manufacturer grants and data fees deserve attention when the payment depends on moving prescriptions or the promised service does not explain the money. Market-share thresholds, volume conditions and manufacturer-funded recommendation programs are concrete connections an insider can recognize.

The Payment Schedule Rewards the Switch

The Amgen allegations connected rebate thresholds to interchange programs. In reviewing an arrangement like that, we connect the contract and its amendments to the rebate schedule, the program’s switching criteria and the reports used to measure performance. The useful question is what the pharmacy had to accomplish to earn the payment.

A clinical employee may know how the preferred drug was presented to prescribers. A contracting employee may know the condition for earning the rebate. A finance employee may know which performance report supported the payment.

The Grant Has a Purchasing Condition

In its 2003 guidance for pharmaceutical manufacturers, the Department of Health and Human Services Office of Inspector General addressed educational funding tied to purchases. It said a purchasing condition raises an anti-kickback concern even when the educational or research purpose is real. It also identified the manufacturer’s influence over a program’s content or presenter as a concern.

We examine the grant’s purpose and approval alongside the pharmacy’s clinical materials and the purchasing expectations attached to the funding.

Data Fees and the Work Behind Them

The inspector general’s guidance says payments for data-collection services should reflect the value of legitimate, reasonable and necessary work. That matters when a manufacturer buys data from a pharmacy that also buys its drugs.

For a pharmacy insider, the useful connection is between the agreement, the data delivered and the payment calculation. We examine those alongside the recommendation program. The same review reaches consulting services: what work was commissioned, what was provided, and why that work commanded that payment.

The inspector general also addressed payments to physicians or others each time a patient’s prescription changed from a competing product to the manufacturer’s drug. The Omnicare allegations give the institutional version a recognizable shape: rebates and other benefits tied to a pharmacy’s influence over drug selection.

Public payment data show only part of that relationship. CMS Open Payments reports transfers of value, while discounts and rebates sit outside its payment file. It also carries no prescription claim. The manufacturer’s contract, the pharmacy’s payment records and the resulting prescriptions fill different parts of the account. That is why an institutional pharmacy inquiry needs the records inside the business.

Why the Government-Paid Prescription Matters

The government-paid prescription connects the manufacturer’s payment to a False Claims Act case. The Anti-Kickback Statute addresses payments or other value used to induce purchases, orders or recommendations involving federal health care programs. Claims resulting from an unlawful kickback can be false claims.

The manufacturer can cause a false claim even when a pharmacy, prescriber or facility submits the bill. In the Amgen and Omnicare allegations, the interchange program targeted Medicaid beneficiaries. That is why the prescription and claim records belong beside the agreement and the program reports: they connect the paid influence to government money.

The role of pharmaceutical whistleblowers with knowledge of those transactions also appears in the broader enforcement history. Public Citizen’s 2018 study of pharmaceutical settlements found that whistleblower revelations contributed, at least in part, to 54% of federal settlements in its 1991-through-2017 review. Those matters accounted for 71% of federal financial penalties in the study. The finding shows how often information brought through whistleblower cases contributed to the government’s pharmaceutical enforcement.

A whistleblower case under the False Claims Act can pay 15% to 30% of what the government recovers.

When You Know What the Pharmacy Was Paid to Recommend

If you know the rebate condition, grant arrangement or data agreement behind a pharmacy’s recommendations, speak with our whistleblower experts about what the payment bought. We work beside you to build your strongest institutional pharmacy kickback case around the transactions and decisions you understand. We stay with you through the whole process and bring in pharmaceutical fraud whistleblower lawyers who know pharmacy kickback cases.